64 related articles for article (PubMed ID: 19412810)
1. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.
Dudek AZ; Murthaiah PK; Franklin M; Truskinovsky AM
Acta Oncol; 2010; 49(1):101-4. PubMed ID: 19412810
[No Abstract] [Full Text] [Related]
2. Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.
Mauri D; Panou C; Valachis A; Kamposioras K; Tsali L
Exp Oncol; 2009 Mar; 31(1):60-1. PubMed ID: 19300420
[TBL] [Abstract][Full Text] [Related]
3. A case of metastatic adamantinoma responding to treatment with pazopanib.
Cohen Y; Cohen JE; Zick A; Orevi M; Doviner V; Rubinstein R; Goldshmidt H; Peylan-Ramu N; Katz D
Acta Oncol; 2013 Aug; 52(6):1229-30. PubMed ID: 23461672
[No Abstract] [Full Text] [Related]
4. Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
Di Lorenzo L
J Clin Oncol; 2007 Jul; 25(19):2858-9; author reply 2859-61. PubMed ID: 17602094
[No Abstract] [Full Text] [Related]
5. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?
Hilbert M; Mary P; Larroquet M; Serinet MO; Helfre S; Brisse H; Coulomb A; Orbach D
Pediatr Blood Cancer; 2012 Mar; 58(3):475-6. PubMed ID: 22234817
[No Abstract] [Full Text] [Related]
6. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib malate.
Izzedine H; Buhaescu I; Rixe O; Deray G
Cancer Chemother Pharmacol; 2007 Aug; 60(3):357-64. PubMed ID: 17136543
[TBL] [Abstract][Full Text] [Related]
8. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
Narayanan S; Callis-Duffin K; Batten J; Agarwal N
Am J Med Sci; 2010 Jun; 339(6):580-1. PubMed ID: 20421784
[TBL] [Abstract][Full Text] [Related]
9. [Lung cancer: molecular targeting therapy].
Kobayashi K
Nihon Kokyuki Gakkai Zasshi; 2004 May; 42(5):371-7. PubMed ID: 15168452
[No Abstract] [Full Text] [Related]
10. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Bavcar S; Argyle DJ
Vet Comp Oncol; 2012 Sep; 10(3):163-73. PubMed ID: 22882485
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
13. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
Neill MG; Wei AC; Jewett MA
Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.
Morimoto AM; Tan N; West K; McArthur G; Toner GC; Manning WC; Smolich BD; Cherrington JM
Oncogene; 2004 Feb; 23(8):1618-26. PubMed ID: 14985702
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
Costero O; Picazo ML; Zamora P; Romero S; Martinez-Ara J; Selgas R
Nephrol Dial Transplant; 2010 Mar; 25(3):1001-3. PubMed ID: 20019017
[TBL] [Abstract][Full Text] [Related]
16. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
Wierzbicka E; Tourani JM; Guillet G
Br J Dermatol; 2006 Jul; 155(1):213-4. PubMed ID: 16792781
[No Abstract] [Full Text] [Related]
17. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
Godbert Y; Henriques de Figueiredo B; Bonichon F; Chibon F; Hostein I; Pérot G; Dupin C; Daubech A; Belleannée G; Gros A; Italiano A; Soubeyran I
J Clin Oncol; 2015 Jul; 33(20):e84-7. PubMed ID: 24687827
[No Abstract] [Full Text] [Related]
18. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
[TBL] [Abstract][Full Text] [Related]
20. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]